Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2

Status

Recruiting 29Active not recruiting 16Not yet recruiting 10Terminated 5Withdrawn 2Completed 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 2Urinary Bladder Neoplasms 1Recurrence 1Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Terminated × sacituzumab govitecan × Clear all
NCT05581589 2026-04-27

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

University of Washington

Phase 2 Terminated
4 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms

NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

NCT04958785 2025-11-04

ELEVATE TNBC

Gilead Sciences

Phase 2 Terminated
92 enrolled 27 charts
Breast

Triple Negative Breast Neoplasms

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

G1 Therapeutics, Inc.

Phase 2 Terminated
30 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

NCT05097599 2025-01-08

StrataPATH

Strata Oncology

Phase 2 Terminated
11 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡